Dallas, TX 11/14/2007 8:06:06 AM
Beacon Equity Research reports on the OTC and OTCBB Trade Leaders: Patient Portal Technologies, Inc. (OTCBB: PPRG), Consolidated Medical Management, Inc. (OTCBB: CMMI), China VoIP & Digital Telecom, Inc. (OTCBB: CVDT), International Fight League ...
To sign up for our free research reports and newsletters, visit http://BeaconEquityResearch.com. For more information on our research programs, please contact: Jeff Bishop at editor@beaconequityresearch.com
Patient Portal Technologies, Inc. (OTCBB: PPRG)
Up 25.00% on Tuesday
Detailed quote: http://beaconequityresearch.com/PPRG
November 13, 2007 - Unity Health System Awards Contract to Patient Portal Technologies for Innovative Broadcast Network of Customized Healthcare Channels
Patient Portal Technologies, Inc. (OTCBB:PPRG) announced today that the Company has been awarded a contract from Unity Health System of Rochester, NY to provide state-of-the-art broadcast technology that enables Unity to deliver customized content through a seven-channel television network showcasing patient education, safety, staff training, and hospital news.
Patient Portal's proprietary HealthCast technology allows for customized content delivery to a single television, groups of televisions, or to every television at multiple facilities systemwide, with further capability for remote delivery of customized content to an IP phone or home computer. The unique digital signage platform allows Unity Health System to deliver condition-specific video content, information scrolls, weather and news, and customized messaging simultaneously, and to vary that content from television to television. Patient Portal's progressive technology also captures all viewing data in real-time to document compliance with government patient education and safety initiatives.
"We are very excited that Unity Health has selected Patient Portal's HealthCast as their systemwide communication platform," said Kevin Kelly, President of Patient Portal Technologies. "It wasn't long ago that this kind of system would have been cost prohibitive for most healthcare facilities, but our technology has changed that. HealthCast delivers cutting-edge media programming that is flexible and affordable so any hospital can achieve customized communication without infrastructure changes or capital outlays. We believe HealthCast will help revolutionize the way healthcare communication is delivered."
"HealthCast is just the flexible solution we were looking for to communicate with patients, families, and staff in real time," said Maryalice Keller, Unity's vice president of Corporate Communications. "Imagine showing a welcome video to a patient, a pediatric clip to a new mom, a training video to a staff member on break, and nutrition content in the cafeterias all at the same time. With HealthCast, we can cost effectively control multiple communication streams throughout all of our facilities and capture viewing metrics. This gives us several opportunities to proactively promote our physicians and healthcare initiatives, consistently train staff, and better educate patients."
Park Ridge Auxiliary at Unity Health has been the driving force and financial motivator behind several key initiatives at Unity, including revamping the communication systems this year. "The Auxiliary is excited to once again fund state-of-the-art technology to benefit patient care at Unity Health System," said Sharlene Penna, president of Unity's Park Ridge Auxiliary. "We take great pride in being a partner in the innovations to patient care offered at Unity."
Consolidated Medical Management, Inc. (OTCBB: CMMI)
Up 23.53% on Tuesday
Detailed quote: http://beaconequityresearch.com/CMMI
November 13, 2007 - CMMI Announces 18-million Share Warrant Reduction
Consolidated Medical Management, Inc. (OTC Bulletin Board: CMMI) today announced that two of its directors relinquished warrants entitling them to purchase up to 18,000,000 shares.
Timothy G. Byrd, Sr., Consolidated Medical Management's chief executive officer and director, and G. C. "Sonny" Wooley, the Company's chairman, had each held common stock purchase warrants permitting them to purchase up to 12,000,000 shares each of CMMI common stock in lieu of compensation accrued during the Company's past non-operational period.
However, in a strong show of support for the Company's future, Mr. Byrd and Mr. Wooley each gave up 9,000,000 of the 12,000,000 shares they were authorized to purchase under the warrants. As a result, once the warrants are exercisable, the Company and its shareholders will realize an 18,000,000 share net reduction in the fully diluted share count.
"When we accepted the warrants earlier this year, we couldn't have predicted the Company's current rate of growth," commented Timothy G. Byrd, Sr., Consolidated Medical Management's chief executive officer. "Mr. Wooley and I believe the Company will benefit many times over from the warrant reduction, further accelerate our growth strategy, and send a clear message to our shareholders that we intend to grow both the Company and shareholder value."
China VoIP & Digital Telecom, Inc. (OTCBB: CVDT)
Up 22.22% on Tuesday
Detailed quote: http://beaconequityresearch.com/CVDT
November 13, 2007 - China VoIP & Digital Telecom, Inc. Subsidiary Reports Record Third Quarter Revenue & Profit
Jinan Yinquan Technology Co., Ltd., a wholly owned subsidiary of China VoIP & Digital Telecom, Inc. (OTCBB: CVDT) today reported operating results for the third quarter ended September 30, 2007. Revenues were $1,899,854 as compared to $152,329 during the same period ended in 2006, an increase of $1,747,525 or 1147%.
During the nine months ended September 30, 2007, the company recorded revenue of $4,155,855 compared to $889,602 during the same period ended in 2006, an increase of $3,266,253 or 367%. Net gain recorded $854,878 during the nine months ended September 30, 2007, representing a 388% or $679,773 increase as compared to $175,105 during the same period of 2006.
The company announced that the increase of revenue and net gain are mainly due to the following reasons: (a) significant revenue increase from rapid development of users, (b) significant decrease of the settlement cost with telecom carriers compared to the same period of last year, (c) better control on selling, general and administrative expenses.
Li Kunwu, President and CEO of China VoIP & Digital Telecom, Inc., attributed the sharp increase in revenue to successful marketing efforts and rapid acceptance of the Company's products and services in newly developed markets. The new markets include Zhejiang, Anhui and Huangshan, which are developed in an orderly way now.
"We now have the capability to handle a significantly greater number of customers for our VoIP products," said Kunwu. "We have developed the Zhejiang Geely Group -- a Hangzhou-China-based auto manufacturer, as our key customer within this period, and we anticipate more and more key-customers as Geely will be developed in the following quarter, which will bring additional increase in revenue."
The complete financial statement will be disclosed on Nov. 14, 2007.
International Fight League (OTCBB: IFLI)
Up 17.86% on Tuesday
Detailed quote: http://beaconequityresearch.com/IFLI
November 13, 2007 - International Fight League Forms Video Sharing Partnership with YouTube and Google Ads
The International Fight League (OTC.BB: IFLI), the world's number one team-based professional mixed martial arts league, and YouTube, the world's leading video sharing Website, today announced a video sharing partnership designed to expose IFL content to a larger worldwide audience. It is the first partnership YouTube has formed in the sport of mixed martial arts, and follows the path of similar partnerships with the NBA, NHL, CBS and EA Sports among others.
"We are very excited to be able to add YouTube and Google Ads as our partners," said IFL co-founder and CEO Gareb Shamus. "Compelling content is key to success, and this partnership gives us the opportunity to expose our athletes, coaches and events to a much larger audience than ever before with compelling content we know this demo loves to view."
The partnership will provide IFL content to thousands of websites around the globe that use Google AdSense and YouTube players. The partnership will also include working with Google and YouTube in a revenue sharing model that would allow the IFL to generate income from advertisements shown in conjunction with its videos. The videos will be available on YouTube as well as other Google AdSense partner sites that cover the sport.
IFL short form videos are already some of the highest volume sports pieces on YouTube, with in excess of over one million views in recent months. This partnership is expected to significantly increase that potential audience.
The first major test of the partnership will occur in the coming week, when the IFL makes the fights from its November 3 World Grand Prix available to the MMA audience for the first time through YouTube. MyNetworkTV showed two of the fights in their live airing on broadcast television; the remaining seven bouts will now be seen for the first time through this partnership.
Grant Life Sciences Inc. (OTCBB: GLIF)
Up 15.00% on Tuesday
Detailed quote: http://beaconequityresearch.com/GLIF
November 13, 2007 - Grant Life Sciences in-licenses HPV DNA-based test from Alphagenics
Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today that it has signed a final agreement with Alphagenics Diaco Biotechnologies S.r.l. (Italy) to exclusively in-license the manufacturing and marketing rights to Alphagenics' molecular diagnostic test for human papillomaviruses (HPVs) in China and the United States and non-exclusively in all other countries.
The Alphagenics HPV test in-licensed by Grant is a DNA-based diagnostic that uses standard molecular diagnostic equipment found in most commercial laboratories. Alphagenics' HPV DNA test complements the HPV blood test that Grant has been developing to detect the presence of antibodies produced only by cancer-causing HPV types. There are some 100 types of HPV; however, only about 7 to 15 HPV-types cause most cervical cancers. While a blood-based test to detect precancerous evidence and cancer of the cervix is still viewed by Grant Life Sciences as the preferred test-methodology to address the needs of the developing world, molecular (DNA) testing is currently the approved test protocol in both the U.S. and Europe to identify the presence of different subtypes of HPV in the cervix.
"Our introduction of the Alphagenics HPV test not only will allow commercial laboratories to provide molecular testing but will also complement the current introduction of vaccines against HPVs," said Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences. "The current approved vaccine in the U.S. provides for inoculation against four types of HPV for use in girls and women 9-to-26 years of age, who presumably have not been exposed to the viruses. However, women who have reached sexual maturity and have not been exposed to one of the four HPV-types may benefit from the vaccination, according to the Advisory Committee on Immunization Practices (ACIP). Consequently, the Alphagenics test will be able to be used by the balance of the female population to determine exposure and the possible use of the vaccine if found negative. Further both vaccines on the market (GSK's vaccine is approved for Australia for ages 10-to-45 and Merck's vaccine is approved in the U.S. for ages 9-to-26) only confer protection against HPV oncogenic types 16 and 18. While these types are predominant (approximately 60+%) in the Caucasian market, there are other types that play significant roles in the Asian, African, Indian, and Hispanic populations. Fortunately, the Alphagenics test is designed to test for all the serotypes of oncogenic HPV."
In addition, Dr. Lin said that the Alphagenics test will be able to be used in the current gynecological regimen to help qualify Pap test results in the case of ambiguous readings, at a cost less than the current approved molecular test. Grant expects to launch the Alphagenics HPV DNA-based test in the Asian and Indian markets during the first quarter of 2008 as an Analyte-Specific Reagent (ASR) to reference laboratories.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN THIS DOCUMENT. ALL INFORMATION PROVIDED HERE IS MERELY INFORMATIONAL AND IS NOT INTENDED TO BE A RECOMMENDATION TO BUY OR SELL ANY SECURITY. YOU SHOULD CONSULT A LICENSED INVESTMENT PROFESSIONAL BEFORE MAKING ANY INVESTMENT DECISION. All material herein has been prepared by us based upon information believed to be reliable. The information contained herein is not guaranteed by us to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not always approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. We are not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed or mentioned herein. Beacon Equity Research has not been compensated by any of the companies covered in this release. It is the policy of Beacon Research and its affiliates to sell any stock received for services, which may cause the stock price to become depressed. Our affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. We may sell shares for less than the target price given in this opinion, or at any time following the issuance of this announcement. We will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Beacon Research and its owners undertake no obligation to update such statements.
